Leucine zipper transcription factor-like 1 expression in gastric cancer and its relationship to relative adhesion molecule

Lian, Xin; Li, Kesheng; Hui-fen, DU; Li, Xingwen; 崔燕,; Chai, Dongqi; Xu, Yang; Rong, Yang

doi:10.4314/tjpr.v16i7.11

Cited by 1 publication

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to statistics, for patients with advanced GC who have undergone advanced systemic therapy, the 5‐year overall survival rate does not exceed 20% . The etiology of GC is a complex process involving multiple genes, and mutation and loss of tumor suppressor genes can promote tumor progression . Therefore, it is important to study the mechanism of GC progression and alternative therapies.…”

Section: Introductionmentioning

confidence: 99%

“…2 The etiology of GC is a complex process involving multiple genes, and mutation and loss of tumor suppressor genes can promote tumor progression. 3 Therefore, it is important to study the mechanism of GC progression and alternative therapies. In addition to surgical treatment, radiotherapy, and chemotherapy, gene therapy and immunotherapy are being studied.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in gastric cancer cells

Tong

Cheng

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

BackgroundImmunotherapy and its mechanisms are being studied in a wide variety of cancers. Programmed cell death ligand 1 (PDL1) is associated with immune evasion in numerous tumor types. Here, we aimed to assess the relationship between metastasis associated in colon cancer‐1 (MACC1) and PDL1 and examine their effects on gastric cancer (GC) tumor immunity.MethodsThe expression of MACC1, c‐Met, and PDL1 in human GC tissues was first assessed using quantitative RT‐PCR (qRT‐PCR) and immunohistochemistry. We then focused on the relationships among MACC1, c‐Met, and PDL1 using RT‐PCR and western blotting after cell transfection and inhibitor treatment in vitro and on the identification of their roles in immune killing in vitro and in vivo.ResultsWe found that expression of MACC1, c‐Met, and PDL1 was upregulated in human GC tissues, and there was a positive correlation between the expression levels. In addition, we found that ectopic expression of MACC1 (silencing and overexpression by transfection) resulted in corresponding changes in c‐Met and PDL1 expression levels, and c‐Met/AKT/mTOR pathway inhibitors (SU11274, MK2206, and rapamycin) blocked the regulation of PDL1 expression by MACC1. Furthermore, silencing of MACC1 led to an increase in antitumor and immune killing in vitro and in vivo, and overexpression of MACC1 resulted in a decrease in tumor immunity in vitro and in vivo.ConclusionsFrom these data, we infer that MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in GC cells and suggest that MACC1 may be a therapeutic target for GC immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%